LAS VEGAS, Dec. 7, 2014 /PRNewswire/ -- BioAdaptives,
Inc. (BDPT) announced results of the recently completed in vivo
trial showing the efficacy of its PrimiCell® product on
muscle repair.
In the study mice were put into groups, PrimiCell®
and the control group. The PrimiCell® group was given
PrimiCell® for seven days prior to the treatment. Both
groups were injected with cardiotoxin in the leg to cause muscle
damage. At day one after the injection, day five, and day seven,
test subjects from each group were analyzed to determine lesion
size, inflammation, necrosis, and overall improvement. Results on
day seven showed the PrimiCell® group had overall
improvement greater than 56% better than the control group. The
results are shown in the graph below.
BioAdaptives, Inc. Chairman and CEO, Barry Epling said, "The results partially
explain the dramatic improvement we are seeing with
PrimiCell® in humans and with animals using Equine
Regen™ and Canine Regen™ which are the targeted animal formulations
derived from the research and clinical trials completed on
PrimiCell®."
Epling further stated, "BioAdaptives remains committed to
further studies and observations of humans, performance horses, and
companion animals."
About BioAdaptives, Inc.
BioAdaptives, Inc. is a fully-reporting, public company trading
on the OTC Bulletin Board under the symbol BDPT. The company is
engaged in research and development in science-based nutraceutical
products for human and animal consumption. The company's focus, in
conjunction with Ferris Holding,
Inc., is to source high quality, unique, raw material worldwide and
develop science-based products to improve health and wellness
in both humans and animals. BioAdaptives, Inc., has developed
a proprietary method that is a non-intrusive bioelectromagnetic
device for improving individual ingredients, food, beverages, and
wellness.
SAFE HARBOR ACT
Forward-Looking Statements: This release contains statements
that constitute forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements appear in a number of places in this release and include
all statements that are not statements of historical fact regarding
the intent, belief or current expectations of BioAdaptives, Inc.
and its directors or its officers with respect to, among other
things: (i) financing plans; (ii) trends affecting its financial
condition or results of operations; (iii) growth strategy and
operating strategy. The words "may," "would," "will," "expect,"
"estimate," "can," "believe," "potential" and similar expressions
and variations thereof are intended to identify forward-looking
statements. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve
risks and uncertainties, many of which are beyond BioAdaptives,
Inc.'s ability to control, and actual results may differ materially
from those projected in the forward-looking statements as a result
of various factors. More information about the potential factors
that could affect the business and financial results is and will be
included in BioAdaptives, Inc.'s filings with the Securities and
Exchange Commission.
Photo -
http://photos.prnewswire.com/prnh/20141208/162778-INFO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bioadaptives-announces-new-trial-showing-primicell-improved-muscle-repair-by-over-56-300005918.html
SOURCE BioAdaptives, Inc.